CAM
ADMA icon

ClariVest Asset Management’s ADMA Biologics ADMA Stock Holding History

ClariVest Asset Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$6.43M Hold
575,251
– – 0.66% 20
2024
Q2 		$6.43M Buy
575,251
+6,026
+1% +$50.5K 0.66% 20
2024
Q1 		$3.76M Buy
569,225
+370,319
+186% +$2.02M 0.39% 46
2023
Q4 		$899K Buy
198,906
+4,728
+2% +$17.5K 0.05% 280
2023
Q3 		$695K Sell
194,178
-256
-0.1% -$985 0.04% 304
2023
Q2 		$718K Buy
+194,434
New +$721K 0.04% 309

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

ClariVest Asset Management's ADMA Position: Q3 2024 in Review

ClariVest Asset Management held its ADMA Biologics (ADMA) position steady in Q3 2024 at 575,251 shares worth $6.43M. The position accounts for 0.66% of the portfolio, ranked #20.

ClariVest Asset Management first reported a position in ADMA in Q2 2023 and has held it in 6 quarters since. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • ClariVest Asset Management held 575,251 shares of ADMA Biologics worth $6.43M as of Q3 2024.
  • ClariVest Asset Management left its ADMA Biologics share count unchanged in Q3 2024.
  • ADMA Biologics made up 0.66% of ClariVest Asset Management's portfolio in Q3 2024, its #20 holding.
  • ClariVest Asset Management first reported a position in ADMA Biologics in Q2 2023 and has held it in 6 quarters since.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.